Advertisement


Jennifer R. Brown, MD, PhD, on CLL/SLL: New Findings on Zanubrutinib vs Ibrutinib for Relapsed or Refractory Disease

2022 ASH Annual Meeting and Exposition

Advertisement

Jennifer R. Brown, MD, PhD, of Dana-Farber Cancer Institute, discusses phase III findings of the ALPINE study, which showed that zanubrutinib is more efficacious and better tolerated than ibrutinib as a treatment for patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). In this first head-to-head comparison of the two BTK inhibitors, the superior progression-free survival of zanubrutinib was observed across all major subgroups, including high-risk patients (Abstract LBA-6).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
The Alpine study is a randomized phase-three trial comparing zanubrutinib to ibrutinib in relapsed/refractory CLL patients. As a reminder, ibrutinib is our first-in-class BTK inhibitor, which has been transformative for CLL therapy but has significant adverse events. Zanubrutinib is a next-generation drug, which is more specific for BTK and also maintains drug levels throughout the dosing interval, potentially allowing greater BTK occupancy. Alpine was designed to assess the efficacy and safety of zanubrutinib in comparison to ibrutinib. The population was an all-comer relapsed/refractory population with a median of one prior therapy, which was chemoimmunotherapy by and large. The randomization was stratified by age, geographic area relapsed/refractory disease, and deletion 17p or TP53 aberrancy. The findings that I presented at ASH this year demonstrated that zanubrutinib has a superior progression-free survival compared to ibrutinib in this setting with a hazard ratio of 0.65 and a two-year landmark of 79% progression-free survival for zanubrutinib versus 67% for ibrutinib, so a 12% improvement. This was seen across all subgroups of disease, but in particular, the high-risk deletion 17p/TP53 aberrant patients had a 22% improvement in their two-year landmark PFS. The median PFS with ibrutinib was reached at 36 months, but not reached with zanubrutinib. In addition to this, zanubrutinib continues to have a higher overall response rate than ibrutinib, which was actually the primary endpoint of the study, but PFS was a key secondary endpoint that we reported here. It was event-driven after 205 events. In terms of safety, zanubrutinib was also safer than ibrutinib. There were fewer drug discontinuations, fewer drug holds, fewer drug interruptions for toxicity. Perhaps most importantly, the cardiac safety was significantly improved with fewer cardiac serious adverse events. Only one drug discontinuation for a cardiac adverse event with zanubrutinib versus 14 for ibrutinib, and perhaps most notably, no cardiac death with zanubrutinib versus six with ibrutinib. In terms of other toxicities, the most common toxicity was neutropenia, which was 23% grade three or higher with zanubrutinib versus 22% with ibrutinib, so pretty comparable, although there were fewer associated infections with zanubrutinib at 9% versus 13% with ibrutinib. COVID-19 was the next most common adverse event and the most common adverse event leading to death at about 4% in zanubrutinib and 5% in ibrutinib. Hypertension was balanced between the arms. So in summary, the Alpine study demonstrated that zanubrutinib has a superior progression-free survival to ibrutinib in relapsed/refractory CLL patients and is also better tolerated with a particularly better cardiac profile, which is one of our key points we worry about with BTK inhibitors. The results of this study are potentially practice-changing, demonstrating that zanubrutinib is a new standard of care for CLL. Are there any follow-up studies you want to mention? Although this was the final analysis of progression-free survival, there will be ongoing analysis and we'll certainly be interested in more mature data as this is about 30 month follow up. We're also interested in studies that are evaluating combination of zanubrutinib and venetoclax, or zanubrutinib and other Bcl-2 inhibitors looking potentially at time limited therapy similar to what's been done with other BTK inhibitors, mostly ibrutinib to date, but also acalabrutinib.

Related Videos

Multiple Myeloma

Paul G. Richardson, MD, on Multiple Myeloma: Mezigdomide Plus Dexamethasone in Relapsed and Refractory Disease

Paul G. Richardson, MD, of the Dana-Farber Cancer Institute, discusses preliminary results from the dose-expansion phase of the CC-92480-MM-001 Trial, which showed promising efficacy in patients with relapsed and refractory multiple myeloma, including those with prior BCMA-targeted therapies. Patients in these two groups had an overall response rate of 40% and 50%, respectively. The results support the development of mezigdomide, currently being evaluated in combination with standard therapies in multiple myeloma as part of a large, ongoing phase I/II trial (NCT03989414) and planned phase III studies (Abstract 568).

Leukemia

Andrew Matthews, MD, on AML: Real-World Effectiveness of 7 + 3 Intensive Chemotherapy vs Venetoclax and a Hypomethylating Agent

Andrew Matthews, MD, of the Abramson Cancer Center, University of Pennsylvania, discusses findings from a large, multicenter study that showed superior outcomes with 7 + 3 chemotherapy (cytarabine continuously for 7 days, along with short infusions of an anthracycline on each of the first 3 days) vs venetoclax in patients with acute myeloid leukemia (AML). In this real-world data set, the 7 + 3 cohort outperformed historical benchmarks in overall survival and early mortality, perhaps reflecting improved later lines of therapy and patient selection. Prospective studies (such as NCT04801797) must confirm the superiority of intensive chemotherapy (Abstract 426).

 

Multiple Myeloma
Immunotherapy

Eileen M. Boyle, MD, PhD, on Multiple Myeloma: Sustained MRD Negativity in Newly Diagnosed Disease Treated with Immunotherapy Regimens

Eileen M. Boyle, MD, PhD, of the Perlmutter Cancer Center, NYU Langone Health, discusses Fc-mediated antibody effector function, inflammation resolution, and oligoclonality and their role in predicting sustained measurable residual disease negativity in patients with newly diagnosed multiple myeloma who were treated with immunotherapy regimens. For the first time, an analysis of T-cell receptors shows that oligoclonal profiles seen on treatment may influence the fitness of the immune response (Abstract 100).

Lymphoma

Jia Ruan, MD, PhD, on Mantle Cell Lymphoma: Phase II Findings on Acalabrutinib/Lenalidomide/Rituximab

Jia Ruan, MD, PhD, of Meyer Cancer Center, Weill Cornell Medicine, and NewYork-Presbyterian Hospital, discusses trial results demonstrating that the triple chemotherapy-free combination of acalabrutinib, lenalidomide, and rituximab is well tolerated, highly effective, and produces high rates of minimal residual disease (MRD)-negative complete response as an initial treatment for patients with mantle cell lymphoma, including those with TP53 mutations. Real-time MRD analysis may enable treatment de-escalation during maintenance to minimize toxicity, which warrants further evaluation. An expansion cohort of acalabrutinib/lenalidomide/obinutuzumab is being launched (Abstract 73).

Lymphoma

Alex F. Herrera, MD, on Previously Untreated DLBCL: Circulation Tumor DNA and Risk Profiling

Alex F. Herrera, MD, of the City of Hope National Medical Center, discusses results from the POLARIX study, which showed that circulating tumor DNA (ctDNA) analysis has prognostic value for patients with previously untreated diffuse large B-cell lymphoma. Patients who did not achieve 2.5 or greater log-fold change and/or did not have ctDNA clearance following one cycle of polatuzumab vedotin along with rituximab, cyclophosphamide, doxorubicin, and prednisone had inferior outcomes than those who did. Early changes in ctDNA levels may be of use in risk-adapted trial designs to identify patients in need of alternative treatment. (Abstract 542).

Advertisement

Advertisement




Advertisement